Video

Dr. Gomella on Labeling Low-Risk Prostate Cancer

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.

Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.

Active surveillance is an appropriate treatment for the majority of those with Gleason six prostate cancer, but often the term ‘cancer’ makes patients feel like they need more aggressive treatment.

Overtreatment is a common problem, which may be solved by renaming the disease, says Gomella.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD